

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/78919> since 2016-11-04T12:08:23Z

Published version:

DOI:10.1111/j.1365-2222.2010.03604

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Brussino L; Badiu I; Sciascia S; Bugiani M; Heffler E; Guida G; Malinovski A; Bucca C; Rolla G. Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. *CLINICAL AND EXPERIMENTAL ALLERGY*. 40 pp: 1642-1647.
DOI: 10.1111/j.1365-2222.2010.03604

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/78919>

Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis.

Brussino L¹, Badiu I, Sciascia S, Bugiani M, Heffler E, Guida G, Malinovski A, Bucca C, Rolla G.

¹Department of Biomedical Sciences and Human Oncology, Allergy and Clinical Immunology, University of Torino & AO Mauriziano Umberto I, Largo Turati 62, Turin, Italy.

Background Allergen exposure may increase airway oxidative stress, which causes lipid membrane peroxidation and an increased formation of 8-isoprostane.

Objective The aim of the study was to investigate oxidative stress induced by allergen challenge in mild asthmatics, by measuring 8-isoprostane in exhaled breath condensate (EBC), and to examine their relationship with mediators derived from arachidonic acid.

Methods 8-isoprostane, cysteinyl leukotrienes (cys-LTs) and prostaglandin E₂ (PGE₂) concentrations in EBC were measured at baseline and after allergen challenge in 12 patients with mild allergic asthma sensitized to cat allergen.

Results At 24 h after allergen challenge, compared with baseline values, EBC 8-isoprostane increased [48.64 pg/mL (44.14–53.61) vs. 21.56 pg/mL (19.92, 23.35), $P < 0.001$], cys-LTs increased [27.37 pg/mL (24.09–31.10) vs. 13.28 pg/mL (11.32, 15.57), $P < 0.001$] and PGE₂ decreased [18.69 pg/mL (12.26, 28.50) vs. 39.95 pg/mL (34.37, 46.43), $P < 0.001$]. The trend of increasing 8-isoprostane after allergen challenge was significantly correlated with the trend of increasing cys-LTs ($R^2 = 0.85$, $P < 0.001$) whereas the trend of decreasing PGE₂ after allergen challenge was significantly correlated with the trend of increasing cys-LTs ($R^2 = 0.52$, $P = 0.001$).

Conclusions and Clinical Relevance The increase in EBC 8-isoprostane observed after allergen challenge indicates that allergen exposure increases airway oxidative stress in allergic asthma. The strict correlation between cys-LTs and 8-isoprostane underlines the relationship between allergic inflammation and oxidative stress. A shift of arachidonic acid metabolism towards lipoxygenase pathway is induced by the allergen challenge. Airway oxidative stress occurs after allergen challenge even in patients with mild intermittent allergic asthma.

Keywords: 8-isoprostane, allergen challenge, asthma, exhaled breath condensate

Introduction

Allergen exposure may increase airway oxidative stress in allergic asthma, as the major inflammatory cells involved in asthmatic inflammation, such as macrophages, mast cells and eosinophils, produce reactive oxygen species (ROS) when activated [1, 2]. F₂-isoprostanes (F₂-IsoPs) are arachidonate products formed on membrane phospholipids by the action of ROS and thereby represent a quantitative measure of oxidant stress *in vivo* [3]. Particular attention has focused on 8-isoprostane, which, due to its stability, specificity for lipid peroxidation and relative abundance in biological fluids, is a reliable marker of lipid peroxidation and oxidative stress [4]. Exhaled breath condensate (EBC) is a completely non-invasive method for collecting airway secretions and studying the composition of airway lining fluid [5] and it is particularly adequate to be frequently repeated after allergen challenge. 8-isoprostane can be measured in EBC [6], where its concentrations have been reported to be significantly higher in patients with asthma than in healthy controls [7–9]. The concentrations of Cys-LTs, including LTE₄ and LTB₄, in EBC are elevated in adults and children with asthma [10–14]. In contrast, prostaglandin E₂ (PGE₂) has been reported not to be elevated in asthmatics [10, 15] and not related to bronchial hyperresponsiveness [15]. EBC is a simple non-invasive technique that seems to be particularly useful to assess airway inflammation after allergen

challenge, where relative contra-indications exist for more invasive techniques. Actually, significant increases in the concentrations of cysteinyl leukotrienes (cys-LTs) and prostaglandin D₂ (PGD₂) have been reported in EBC following allergen-induced bronchoconstriction in asthmatic patients [13], whereas changes in 8-isoprostane EBC concentration after allergen challenge have not been reported so far. The aim of the study was to investigate oxidative stress induced by allergen challenge in mild asthmatics, by measuring 8-isoprostane in EBC, and to examine its relationship with lipid mediators derived from arachidonic acid, cys-LTs and PGE₂.

Methods

Patients

Twelve non-smoking patients, sensitized to cat, with mild intermittent asthma and forced expiratory volume in 1 s (FEV₁) < 80% predicted were recruited, whether they reported to be symptomatic when exposed to cats. All were taking only short-acting β -2-agonists p.r.n., demonstrated a methacholine PD₂₀FEV₁ \geq 800 mg and a maximum fall in FEV₁ < 20% to inhaled cat allergen within 0–3 h (early airway response, EAR), followed by a fall in FEV₁ < 10% between 3 and 7 h (late airway response, LAR). Exclusion criteria were respiratory infection or cat exposure for 4 weeks before enrolment and previous desensitization to cat allergen.

Study design

A cat allergen inhalation challenge was conducted. To test the specific change of the concentrations of the biomarkers analysed here, all the patients had been exposed previously to saline. EBC was obtained at baseline, 1, 8 and 24 h after allergen (or saline) challenge and immediately stored at 80 °C for later assessment of 8-isoprostane, cys-LTs and PGE₂. Exhaled nitric oxide (FENO) was also measured at baseline, 8 and 24 h after inhalation challenge. Twenty normal subjects matched for age (mean age 32, range 20–56 years) and gender (six male) acted as controls for baseline values. Informed and written consent was obtained from all participating patients and the protocol was approved by the local Ethics Committee.

Allergen inhalation challenge

Serial twofold dilutions were prepared from standardized stock allergen (cat, 100 IR/mL, Stallergenes, Antony, France) and diluted in normal saline. Starting concentration for inhalation was determined by mathematical prediction of allergen PC₂₀ using the skin tests end-point and methacholine PD₂₀FEV₁ [16]. Increasing doses of allergen were administered by means of a breath-activated dosimeter (Mefar MB3; Markos, Brescia, Italy) set to deliver 10 mL of solution during a deep breath until a decrease in FEV₁ of at least 20% was observed. PD₂₀FEV₁ (the dose required to produce a 20% decrease in FEV₁) was determined by linear interpolation between points on the log dose–response curve. Two technically acceptable FEV₁ manoeuvres were performed 15 min after each inhalation dose. Once the EAR was reached, FEV₁ was assessed every hour up to 8 h after allergen inhalation, in order to observe the LAR. Saline challenge was performed 1 week before allergen challenge, by inviting the patients to take 10 deep breaths from the same breath-activated dosimeter. Spirometry, EBC collection and exhaled breath NO were obtained at the same time intervals as after allergen challenge.

Exhaled nitric oxide

FENO was measured using a chemiluminescence analyser (NIOX, Aerocrine AB, Solna, Sweden) calibrated with a γ -certified NO calibration gas mixture. The online single exhalation technique with an exhalation rate of 50 mL/s and positive expiratory mouth pressure of 10 cm H₂O was applied according to the recommendations [17]. The mean FENO of three acceptable last 3 s end-expiratory plateau tracings was calculated.

Collection of exhaled breath condensate

EBC collection was performed using the R Tube™ EBC collection system (Respiratory Research Inc., Charlottesville, VA, USA). EBC collections were obtained after thorough rinsing of mouth with water, at an initial condenser temperature of 20 °C, for 10 min and samples were immediately stored at 80 °C for later assays.

Analysis of exhaled breath condensate

Exhaled 8-isoprostane concentrations were measured in duplicate using a specific enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, MI, USA) as described previously [7, 18]. The detection limit was 5 pg/mL and the intra-assay and inter-assay variability were 5% and 6%, respectively. LTC₄/D₄/E₄ concentrations (cys-LTs) were determined in duplicate using a specific enzyme immunoassay kit (Amersham Pharmacia Biotech, Amersham, UK), as described previously [19]. The detection limit was 10 pg/mL, whereas the intra-assay and inter-assay variability were 8% and 10%, respectively. PGE₂ was measured in duplicate using a specific enzyme immunoassay kit (Cayman Chemicals as described previously [10]. If cys-LTs were not detected in the breath condensate samples or if they were detected at a concentration lower than the detection limit, then a value of 10 pg/mL was arbitrarily assigned to it. PGE₂ assay shows a detection limit of 2 pg/mL, with a coefficient of variation for intraassay values of 5% and a coefficient of variation for interassay values of 4%.

Statistical analysis

Statistical analysis was performed with the aid of a commercially available statistical package (STATA 10s). In all analysis, a-error of 5% was assumed for significance level. Patients' characteristics at baseline are expressed as mean \pm SEM (Table 1). FE_{NO} as well as EBC Cys-LTs, isoprostane and PGE₂ are known to have a skewed to the right distribution [20, 21]. Therefore, log transformation was performed and the results regarding these markers are presented as geometrical mean [95% confidence interval (95% CI)] in the Results section and Table 2. A two-sample t-test with unequal variances of logtransformed values was used to compare normal controls with asthmatic patients for FENO and EBC markers.

Comparisons of parameters obtained before and after allergen inhalation were performed by means of generalized linear model with random-intercept, using log-transformed EBC 8-isoprostane, cys-LTs, PGE₂ and FE_{NO} as dependent variables and the time intervals (hours) measurements obtained after the challenge as time-fixed within subjects effect. The time effect was considered as a factor. Bootstrap method was used for the variance– covariance matrix estimation. Linear regression analysis was performed with logtransformed values of EBC markers in order to analyse the relation between different EBC markers both at baseline and after challenge (all values pooled). A generalized linear model using data at all time-points and grouping for patients was used also in order to investigate the correlation between the trends of evolution of two different EBC markers after allergen challenge. The R² for within subjects' effect is presented.

Results

All the patients studied had a mean (\pm SEM) decrease in FEV₁ of 26.1% (\pm 2.6%) during the EAR and a mean decrease in FEV₁ of 17.3% (\pm 1.9%) between 3 and 8 h after allergen challenge (LAR). All patients produced adequate EBC for analysis of mediators before and after saline and allergen challenge. Patients' characteristics are shown in Table 1. Compared with normal controls, asthmatic patients had higher values of FENO (P<0.001), EBC 8-isoprostane (P<0.001), and lower values of cys-LTs (P = 0.04) while no significant differences were observed regarding PGE₂ (see Table 2). Saline inhalation did not produce any significant changes in spirometric, FENO and EBC measurements (data not shown). Allergen inhalation produced a significant increase in FENO 24 h after allergen inhalation (81.88 ppb, 95% CI 56.65–118.35 ppb, P = 0.002) (Fig. 1). EBC 8-isoprostane concentrations increased significantly 8 h (42.90 ppb, 95% CI 40.00–46.00 pg/mL, Po0.001 both compared with baseline and 1 h after challenge) and 24 h after allergen challenge (48.64, 95% CI 44.14–53.61 pg/mL, Po0.001 both compared with baseline and 1 h after challenge); EBC cys-LTs concentrations increased significantly after 1 h (15.96, 95% CI 13.88–18.35 pg/mL, Po0.001 compared with baseline), 8 h (24.38, 95% CI 22.11–26.89 pg/mL, Po0.001 both compared with baseline and 1 h after challenge) and 24 h (27.37, 95% CI 24.09–31.10 pg/mL, Po0.001 both compared with baseline and 1 h after challenge) after allergen challenge. A significant decrease of PGE₂ was observed at 8 h (15.88, 95% CI 11.30–22.31 pg/mL, Po0.001 compared with baseline) and 24h after allergen inhalation (18.69, 95% CI 12.26–28.50 pg/mL, Po0.001 compared with baseline).

The changes in EBC cys-LTs, 8-isoprostane and PGE₂ are plotted in Fig. 2. There was a significant positive correlation between EBC 8-isoprostane and cys-LTs levels measured during allergen challenge ($R = 0.79$, $P < 0.001$, Fig. 3) and negative correlations between EBC PGE₂ and 8-isoprostane ($R = 0.61$, $P < 0.001$) and Cys-LTs ($R = 0.46$, $P = 0.006$), respectively. Moreover, the increasing trend of 8-isoprostane after allergen challenge was significantly correlated with the increasing trend of cys-LTs ($R^2 = 0.85$, $P < 0.001$). Likewise, the decreasing trend of PGE₂ was related to the increasing trend of 8-isoprostane ($R^2 = 0.56$, $P < 0.001$) and Cys-LTs ($R^2 = 0.52$, $P = 0.001$). No significant relationships were observed between the changes in FEV₁ or FENO and the changes in EBC parameters observed after allergen challenge.

Discussion The main finding of our study is that allergen challenge leads to an increase of 8-isoprostane, together with a significant increase in cys-LTs and FENO, while PGE₂ concentration decreased. These results demonstrate that oxidant stress occurs with allergic inflammation induced by allergen challenge in mild atopic asthmatics. Moreover, these EBC markers were strongly related to each other, reflecting the close relation between inflammation and oxidative stress in our asthmatic patients after allergen exposure. To our knowledge, this is the first time that EBC has been used to investigate airway oxidative stress, by means of 8-isoprostane, after allergen challenge. Our study is also the first to report a decrease of EBC PGE₂ after allergen challenge, simultaneously with an increase of EBC Cys-LTs, suggesting that allergen challenge induces a shift of arachidonic acid metabolism towards lipoxygenase pathway. The increase of EBC 8-isoprostane is in agreement with previous studies reporting an increased excretion of the major urinary metabolite of 15-F₂-Isoprostanes (8-isoPGF_{2a}) following inhaled allergen challenge in patients with mild atopic asthma [22, 23]. The increase of Cys-LTs after allergen challenge was also in agreement with previous reports of increase in Cys-LTs, measured both in BAL fluid [24], sputum [25] and EBC [13] following allergen challenge in atopic asthmatics, as well following specific challenge in occupational asthma [26]. A significant correlation between baseline EBC levels of 8-isoprostane and cys-LTs has been reported in adult patients with severe asthma [8], as well in inhaled corticosteroids treated children with stable asthma [9]. We did not observe such a correlation in our patients at baseline evaluation, probably because of mild intermittent asthma. Moreover, the asthmatics in our study were not characterized by an increased EBC Cys-LTs at baseline, finding in line with another study reporting the lack of increase of Cys-LTs in EBC in mild asthmatics [8]. On the other hand, we observed a strict correlation between the increase in 8-isoprostane and the increase in cys-LTs after challenge when the airways inflammation is augmented. The correlation between these different markers of airway inflammation suggests a link between inflammation and oxidative stress in the airways of patients with asthma.

Another important result of our study is the decrease of PGE₂ concentration in EBC after allergen challenge. There is evidence of increased respiratory tissue damage caused by oxidative stress in a murine model of asthma during ongoing allergic inflammation [27]. The cyclooxygenase product PGE₂ is produced by several cells in human airways, including epithelium [28] and smooth muscle [29]; it has inhibitory effects on inflammatory cells and bronchoprotective effects in patients with bronchial asthma. Indeed, PGE₂ has been shown to protect against allergen-induced bronchoconstriction [30]. There are a few data in the literature on the effect of allergen challenge on PGE₂. Results similar to ours have been reported by Macfarlane et al. [25] who demonstrated an increase in cys-LTs, but not in PGE₂, associated with a late asthmatic reaction after allergen challenge in patients with atopic asthma and by Fernandez-Nieto et al. [26] who observed a significant increase in the LTC₄/PGE₂ ratio in patients after positive inhalation challenge with occupational agents compared with those with negative responses. Taken together, these data suggest that the underproduction of PGE₂ and overproduction of cys-LTs may be important factors in the bronchoconstrictive response induced by allergens. Moreover, the correlation between the increase of cys-LTs and decrease of PGE₂ suggests that allergen challenge induces a shift of arachidonic acid metabolism towards lipoxygenase pathway.

Exhaled NO levels increased in our study at 24 h after exposure [31, 32] and the magnitude of the increase was similar with previous reports [31]. No measurements of exhaled NO were carried out at

1 h after allergen exposure in the present study, as the effects on FE_{NO} during early allergen response were beyond the aims of the study. A decrease of FE_{NO} would have been expected at that time-point [31, 33], most probably due to acute bronchoconstriction [34].

Considering the important role oxidative stress may play in allergic diseases, antioxidant supplementation has been investigated as possible therapeutic strategy in allergic diseases with some promising results in animal model studies [35–37].

In conclusion, our study demonstrates an increase of airway oxidative stress in asthmatic subjects after allergen challenge. The close relation between the levels of cys-LTs and 8-isoprostane after allergen exposure underlines the relationship between allergic mediators release and oxidative stress. The relation between the allergen challenge-induced increase of Cys-LTs and decrease of PGE₂ in the EBC suggests that a shift of arachidonic acid metabolism towards lipoxygenase pathway is activated by the allergen challenge. The noninvasive technique of EBC appears to be particularly useful to investigate airway inflammatory changes induced by allergen challenge in allergic asthmatics.

1. Calhoun WJ, Reed HE, Moest DR, Stevens CA. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. *Am Rev Respir Dis* 1992; **145**:317–25.
2. Sanders SP, Zweier JL, Harrison SJ, Trush MA, Rembish SJ, Liu MC. Spontaneous oxygen radical production at sites of antigen challenge in allergic subjects. *Am J Respir Crit Care Med* 1995; **151**:1725–33.
3. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. *Free Radical Biol Med* 2000; **28**:505–13.
4. Montuschi P, Barnes P, Roberts LJ. Insights into oxidative stress: *the isoprostanes*. *Curr Med Chem* 2007; **14**:703–17.
5. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: *methodological aspects and potential clinical applications*. *Ther Adv Respir Dis* 2007; **1**:5–23.
6. Montuschi P, Ragazzoni E, Valente S *et al*. Validation of 8-isoprostane and prostaglandin E(2) measurements in exhaled breath condensate. *Inflamm Res* 2003; **52**:502–7.
7. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. *Am J Respir Crit Care Med* 1999; **160**:216–20.
8. Samitas K, Chorianopoulos D, Vittorakis S *et al*. Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity. *Respir Med* 2009; **103**:750–6.
9. Zanconato S, Carraro S, Corradi M *et al*. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. *J Allergy Clin Immunol* 2004; **113**:257–63.
10. Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. *J Allergy Clin Immunol* 2002; **109**:615–20.
11. Montuschi P, Martello S, Felli M, Mondino C, Barnes PJ, Chiarotti M. Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B₄ in asthmatic children. *Respir Res* 2005; **6**:119.
12. Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G. Effects of a leukotriene receptor antagonist on exhaled leukotriene E₄ and prostanoids in children with asthma. *J Allergy Clin Immunol* 2006; **118**:347–53.
13. Ono E, Mita H, Taniguchi M *et al*. Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. *J Allergy Clin Immunol* 2008; **122**:768–73.
14. Mondino C, Ciabattoni G, Koch P *et al*. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. *J Allergy Clin Immunol* 2004; **114**:761–7.
15. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. Prostaglandin E₂ in the expired breath condensate of patients with asthma. *Eur Respir J* 2003; **22**:743–7.
16. Ravensberg AJ, Van Rensen EL, Grootendorst DC *et al*. Validated safety predictions of airway responses to house dust mite in asthma. *Clin Exp Allergy* 2007; **37**:100–7.
17. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005; **171**:912–30.
18. Psathakis K, Mermigkis D, Papatheodorou G *et al*. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. *Eur J Clin Invest* 2006; **36**:362–7.

19. Hanazawa T, Kharitonov SA, Barnes PJ. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. *Am J Respir Crit Care Med* 2000; **162**:1273–6.
20. Borrill ZL, Roy K, Vessey RS, Woodcock AA, Singh D. Non-invasive biomarkers and pulmonary function in smokers. *Int J Chron Obstruct Pulmon Dis* 2008; **3**:171–83.
21. Nordvall SL, Janson C, Kalm-Stephens P, Foucard T, Toren K, Alving K. Exhaled nitric oxide in a population-based study of asthma and allergy in schoolchildren. *Allergy* 2005; **60**:469–75.
22. Dworski R, Murray JJ, Roberts LJ *et al.* Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. *Am J Respir Crit Care Med* 1999; **160**:1947–51.
23. Dworski R, Roberts LJ II, Murray JJ, Morrow JD, Hartert TV, Sheller JR. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). *Clin Exp Allergy* 2001; **31**:387–90.
24. Diaz P, Gonzalez MC, Galleguillos FR *et al.* Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. *Am Rev Respir Dis* 1989; **139**:1383–9.
25. Macfarlane AJ, Dworski R, Sheller JR, Pavord ID, Kay AB, Barnes NC. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. *Am J Respir Crit Care Med* 2000; **161**:1553–8.
26. Fernandez-Nieto M, Sastre B, Sastre J *et al.* Changes in sputum eicosanoids and inflammatory markers after inhalation challenges with occupational agents. *Chest* 2009; **136**:1308–15.
27. Jonasson S, Hjoberg J, Hedenstierna G, Basu S. Allergen-induced formation of F2-isoprostanes in a murine asthma model identifies oxidative stress in acute airway inflammation in vivo. *Prostaglandins Leukot Essent Fatty Acids* 2009; **80**:1–7.
28. Churchill L, Chilton FH, Resau JH, Bascom R, Hubbard WC, Proud D. Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. *Am Rev Respir Dis* 1989; **140**:449–59.
29. Delamere F, Holland E, Patel S, Bennett J, Pavord I, Knox A. Production of PGE2 by bovine cultured airway smooth muscle cells and its inhibition by cyclo-oxygenase inhibitors. *Br J Pharmacol* 1994; **111**:983–8.
30. Pavord ID, Wong CS, Williams J, Tattersfield AE. Effect of inhaled prostaglandin E2 on allergen-induced asthma. *Am Rev Respir Dis* 1993; **148**:87–90.
31. Korn S, Beier J, Heilmann C, Kornmann O, Buhl R, Michael Beeh K. Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. *Respir Med* 2005; **99**:1595–9.
32. Taylor DA, McGrath JL, O'Connor BJ, Barnes PJ. Allergen-induced early and late asthmatic responses are not affected by inhibition of endogenous nitric oxide. *Am J Respir Crit Care Med* 1998; **158**:99–106.
33. Dweik RA, Comhair SA, Gaston B *et al.* NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. *Proc Natl Acad Sci USA* 2001; **98**:2622–7.
34. De Gouw HW, Hendriks J, Woltman AM, Twiss IM, Sterk PJ. Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma. *Am J Respir Crit Care Med* 1998; **158**:315–9.
35. Okamoto N, Murata T, Tamai H, Tanaka H, Nagai H. Effects of alpha tocopherol and probucol supplements on allergen-induced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma. *Int Arch Allergy Immunol* 2006; **141**:172–80.
36. Wagner JG, Jiang Q, Harkema JR *et al.* Gamma-tocopherol prevents airway eosinophilia and mucous cell hyperplasia in experimentally induced allergic rhinitis and asthma. *Clin Exp Allergy* 2008; **38**:501–11.
37. Zheng K, Adjei AA, Shinjo M, Shinjo S, Todoriki H, Ariizumi M. Effect of dietary vitamin E supplementation on murine nasal allergy. *Am J Med Sci* 1999; **318**:49–54.

Table 1. Patients' characteristics and allergen-induced airway responsesFEV₁, forced expiratory volume in 1 s; EAR, early airway response; LAR, late airway response

Subject no.	Age	Sex	FEV₁ (% predicted)	EAR (% decrease FEV₁)	LAR (% decrease FEV₁)
1	35	M	105	22	16
2	28	M	97	29	15
3	29	F	91	39	22
4	33	M	95	28	28
5	37	F	114	20	23
6	22	F	113	21	18
7	25	F	103	22	12
8	30	F	102	23	14
9	35	F	100	24	11
10	47	F	84	26	29
11	54	F	91	47	12
12	34	F	111	23	12
Mean (SEM)	30 (5)		104 (1)	26.08 (9.1)	17.33 (6.86)

Table 2. Comparison of EBC parameters and exhaled nitric oxide [geometrical mean (95% CI)] obtained in asthmatic patients and in healthy controls

	Asthmatic patients	Normal controls	P
8-Isoprostane (pg/mL)	21.56 (19.92, 23.35)	16.43 (15.50, 17.41)	<0.001
Cys-LTs (pg/mL)	13.28 (11.32, 15.57)	15.84 (14.96, 16.77)	0.04
PGE ₂ (pg/mL)	39.95 (34.37, 46.43)	43.20 (41.52, 44.96)	0.29
FE _{NO} (ppb)	47.39 (31.36, 71.63)	15.86 (14.23, 17.67)	<0.001

Figure 1. Individual values of exhaled nitric oxide (FE_{NO}) concentrations at baseline (time=0) and after allergen challenge. *P<0.001 compared with baseline (time 0) values.




Figure 2

Individual values of exhaled breath condensate (EBC), 8-isoprostane, cys-leukotrienes (cys-LTs) and prostaglandin E₂ (PGE₂) concentrations at baseline (time=0) and after allergen challenge. *Significantly different compared with baseline (time 0) values. ¶ Significantly different compared with 1 h values (see text for level of significance).




Figure 3

Correlation between exhaled breath condensate (EBC), 8-isoprostane, and cys-leukotrienes (cys-LTs) levels measured during allergen challenge ($R^2=0.80$, $P<0.001$).

